Navigation Links
New Drug Boosts 'Good' Cholesterol in Study Patients
Date:9/13/2011

TUESDAY, Sept. 13 (HealthDay News) -- A treatment currently being studied may prevent progression of atherosclerosis, a condition caused by the build-up of plaque in artery walls that can lead to heart attack, according to new research.

In conducting the study, published in the Sept. 12 issue of The Lancet, researchers followed 130 patients with atherosclerosis who were randomly assigned to be treated with either the experimental heart drug dalcetrapib, or an inactive placebo over the course of two years. In the double-blind study, neither the researchers nor the patients knew who was taking the heart drug and who was taking the placebo.

While statin drugs are commonly used to lower LDL or "bad" cholesterol to reduce the risk of coronary artery disease, dalcetrapib raises HDL or "good" cholesterol in order to reduce the risk, the researchers explained.

To determine the efficacy of dalcetrapib, the researchers used non-invasive imaging technology. Through MRI, the researchers found the patients on dalcetrapib had a 31 percent increase in "good" HDL cholesterol levels. Additional PET/CT scans showed that inflammation levels in the carotid artery of patients were significantly reduced only among those taking dalcetrapib. The carotid arteries are responsible for supplying oxygenated blood to the head and neck.

In a different study, a drug in the same class designed to raise HDL levels was tied to an increase in death linked to vascular inflammation, but the researchers did not find an increase in such inflammation with dalcetrapib.

"This milestone study shows that MRI and PET/CT are highly useful in assessing the safety and efficacy of dalcetrapib, and that this novel therapy may address a significantly unmet need in cardiovascular disease," said lead study author Zahi A. Fayad, a professor of radiology and medicine in the cardiology division at Mount Sinai School of Medicine and the director of its Translational and Molecular Imaging Institute, in a Mt. Sinai news release.

"We are excited about the results obtained in this trial, which could have a great impact on the treatment of patients with cardiovascular disease," said Fayad, who disclosed receiving financial compensation as a scientific advisory board member from the study's sponsor, Hoffmann-La Roche, whose holding company makes dalcetrapib.

Fayad noted imaging technology could be a vital tool for evaluating other treatments for heart disease.

More information

The U.S. National Library of Medicine has more about atherosclerosis.

-- Mary Elizabeth Dallas

SOURCE: Mount Sinai Hospital, news release, Sept. 12, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. TNF Treatment for Rheumatoid Arthritis Boosts Skin Cancer Risk
2. Regular Exercise Boosts the Brain, Too
3. Yoga boosts stress-busting hormone, reduces pain: York U study
4. Stopping Daily Aspirin Boosts Heart Attack Risk: Study
5. Study: Potassium Boosts Heart Health, Salt Harms It
6. Even One Glass of Beer, Wine Boosts Car Crash Risk: Study
7. Mystery ingredient in coffee boosts protection against Alzheimers disease
8. On-the-Job Activity Boosts Americans Exercise Levels
9. Weight Loss in Heavy, Obese Women Boosts Vitamin D Levels
10. Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women
11. Tai Chi Prevents Falls, Boosts Mental Health in Seniors: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Boosts 'Good' Cholesterol in Study Patients
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV ... the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream ... Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... to announce the addition of micro-needling services in their Napa Valley office. The ... founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: ... wait longer to access the treadmills. It’s a predictable trend. After the excesses of ... and get in shape by joining gyms, starting new walking or running routines, or ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... Chairman and CEO, will be presenting at Source Capital Group,s ... York, NY at 2:15 p.m. ET on Wednesday, ... Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... approximately one hour after the conclusion of the live event. ...
(Date:2/5/2016)... Feb. 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... previously announced underwritten secondary offering of 11,027,558 shares of ... of affiliates of Blackstone and Goldman Sachs.  The shares ... price of $96.45 per share. The selling stockholders will ... Zimmer Biomet nor any of its directors, officers or ...
(Date:2/5/2016)... France , Germany ... and Israel ). It includes a 10-year epidemiology forecast ... segmented by age and sex in these markets. GD epidemiology report is ... in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends ... Germany , Italy , Spain ...
Breaking Medicine Technology: